AstraZeneca Has Most MedImmune Shares
The company says 96% of the stock has been tendered toward its acquisition.
AstraZeneca
(AZN) - Get Report
said Friday that virtually all stockholders of
MedImmune
(MEDI)
have tendered their shares to its takeover offer, essentially completing its $15.6 billion acquisition of the Maryland-based drug and vaccine company.
AstraZeneca said 96% of MedImmune's shares had been tendered by the Thursday midnight deadline for the $58-a-share offer price. Stragglers will have until midnight June 5 to tender their shares at the same price.
The acquisition, announced in late April, was approved by the Federal Trade Commission on May 29. AstraZeneca said the deal is expected to close on or about June 18.
